Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients

Woo Jin Jung1, Sangmi Jang1, Won Joon Choi3, Jaewon Park3, Gwang Hyeon Choi1, Eun Sun Jang2, Sook-Hyang Jeong1,2, Won Seok Choi1,3, Jae Hwan Lee1,3, Chang Jin Yoon1,3 & Jin-Wook Kim1,2*

Transarterial chemoembolization (TACE) is often used as a locoregional therapy for early hepatocellular carcinoma (HCC) when local ablation or resection are not feasible, but incomplete response and recurrence are commonly observed. In this study, we sought to determine the association between metformin administration and TACE outcomes for single nodular HCC in patients with type 2 diabetes mellitus (T2DM). The retrospective cohort analysis included 164 T2DM patients with single nodular HCC who underwent TACE as an initial treatment, and 91 were exposed to metformin before and after TACE. Propensity score (PS) matching was used to balance covariates. Logistic regression analysis was used to determine the predictors of tumor response after TACE, and Cox regression analysis assessed independent predictors of local tumor recurrence (LTR) in patients with complete response after TACE. Metformin use was associated with significantly higher objective response rate (ORR) in the overall and PS-matched cohort (79.1% vs. 60.3 and 78.7% vs. 57.5%; p = 0.008 and p = 0.029, respectively). Logistic regression analysis showed that metformin use was an independent predictor of ORR in all and PS-matched patients (odds ratio = 2.65 and 3.06; p = 0.016 and 0.034, respectively). Cox regression analysis showed metformin administration was an independent predictor for lower LTR in all and PS-matched patients (hazard ratio = 0.28 and 0.27; p = 0.001 and 0.007, respectively). Metformin administration is associated with better initial response and lower local recurrence after TACE for single nodular HCC in T2DM.

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is the fourth leading cause of cancer death worldwide. Treatment of HCC includes locoregional and systemic therapy depending on the tumor stage and the functioning hepatic reserve. Transarterial chemoembolization (TACE) is the most frequently used locoregional therapy for patients with intermediate-stage HCC. In addition, early HCC may also be indicated for TACE if surgery or local ablation are not feasible. However, the local control rate of TACE ranges from 57 to 80%, and the long-term recurrence-free rate is only 17%–35% in early HCC. Combined radiofrequency ablation (RFA) may enhance TACE’s response rate, but there is a concern for the risk of complications. Therefore, it is clinically relevant to develop strategies to enhance the response rate of TACE in early HCC.

Metformin, a first-line treatment for type 2 diabetes mellitus (T2DM), has received attention as a preventive measure in several cancers, including HCC. Retrospective observational studies and meta-analyses have shown...
that metformin reduces the risk of developing HCC in patients with diabetes\(^{16-18}\). In addition to its preventive effect, several preclinical studies have reported that metformin may enhance the effect of cytotoxic drugs, radiofrequency ablation, or radiation therapy for HCC\(^{19-23}\). However, the effect of metformin in known HCC patients is less extensively studied. Retrospective cohort studies reported that the combination with metformin did not increase the antitumor effect of sorafenib\(^{24,25}\), and the impact of metformin on the HCC survival is controversial\(^{26-31}\). It is also not known whether metformin affects the outcomes of TACE. In this study, we aimed to assess whether metformin affects therapeutic outcomes of TACE for early HCC in patients with T2DM.

**Result**

**Study population.** During the study period, 1,001 treatment-naïve patients with single nodular HCC underwent TACE as an initial treatment. After excluding patients with incomplete follow-up imaging data, vascular or ductal invasion or distant metastasis, Child–Pugh C, no diabetes or combined radiofrequency ablation, 164 patients were finally included for analysis (Fig. 1). Out of them, 91 were on metformin before TACE. After PS matching, 94 patients were selected for comparison: 47 in control and 47 in metformin group.

In the PS-matched metformin group, all patients received metformin at least for one day during the admission period for TACE, and 58 percent of patients received metformin on the day of TACE procedure. After TACE, 60 and 38 percent of patients were confirmed to maintain metformin for at least 6 months after TACE and till the end of follow-up, respectively. In the metformin group, the median duration of documented metformin therapy before TACE was 32 months (5.5 months for PS-matched patients), ranging 1–177 months (1–137 months for PS-matched patients). The median dose of metformin was 250 mg/day (range 250–1000 mg/day).

The baseline characteristics of the patients are shown in Table 1. Patients on metformin were older of age, had less frequent viral etiology of liver disease, higher rate of prescription for DPP-4 inhibitors and SGLT2 inhibitors than control. Metformin group also showed better liver function indicators (higher platelet counts, lower prothrombin time, lower bilirubin, better Albumin-Bilirubin [ALBI] grades\(^{32}\), higher BCLC staging, and larger tumor size. However, the differences between the two groups became insignificant after propensity score matching.

**Pre-TACE metformin administration as a predictor of the favorable initial response of TACE.** Table 2 shows the radiological response rate of overall and PS-matched patients according to mRE-CIST criteria 4 weeks after initial TACE. Metformin group had a higher objective response, i.e., sum of complete response (CR) and partial response (PR), than control: 79.1% vs. 60.3%, odds ratio (OR) 2.50, \(p = 0.009\) for all patients, and 78.7% vs. 57.5%, OR 2.74, \(p = 0.029\) for PS-matched patients. CR was not statistically different between the two groups (OR 1.11, \(p = 0.738\) for all patients, and OR 1.00, \(p = 1.000\) for PS-matched patients).

Logistic regression analysis showed that metformin use was an independent predictor of objective response, along with tumor size in both overall (OR 2.65, 95% CI 1.20–5.84, \(p = 0.016\)) and PS-matched (OR 3.06, 95% CI 1.09–8.59, \(p = 0.034\)) patients (Supplementary Tables 1 and 2). The daily dose of metformin did not have significant effect on TACE response in overall patients (OR 2.14, \(p = 0.174\)), but patients with daily metformin dose > 500 mg had higher objective response in PS-matched group (OR 6.27, \(p = 0.049\)).

Metformin use was associated with a low incidence of local tumor recurrence after TACE. Overall, 90 out of 164 patients (54.9%) achieved CR after single session of TACE. Of these patients with CR, the overall recurrence and local recurrence rates were 70.0% and 47.8%, respectively. Kaplan–Meier analysis showed that local tumor recurrence (LTR) was significantly lower in patients taking metformin than in patients without metformin administration before TACE (\(p = 0.003\)) (Fig. 2A). However, the overall recurrence
| Variables                      | Before PS matching | Metformin (n=91) | p value/SMD | After PS matching | Metformin (n=47) | p value/SMD |
|-------------------------------|--------------------|------------------|-------------|------------------|------------------|-------------|
|                              | Control (n = 73)   | Metformin (n = 91) |             | Control (n = 47)  | Metformin (n = 47) |             |
| Age, years                    | 67 (16)            | 71 (18)          | 0.073 – 0.288 | 67 (16)          | 71 (18)          | 0.615 – 0.104 |
| Male gender                   | 57 (78)            | 71 (78)          | 0.993 0.001  | 38 (81)          | 37 (79)          | 0.797 0.053  |
| Heavy alcohol consumption     | 19 (26)            | 29 (32)          | 0.414 0.129  | 15 (31)          | 16 (33)          | 0.827 0.045  |
| Comorbidities                 |                    |                  |             |                  |                  |             |
| Hypertension                  | 27 (37)            | 27 (30)          | 0.322 0.156  | 18 (38)          | 12 (25)          | 0.186 0.272  |
| Cardiopulmonary disease**     | 9 (12)             | 16 (18)          | 0.352 0.148  | 7 (15)           | 7 (15)           | 1.000 0.000  |
| CKD                           | 12 (16)            | 16 (18)          | 0.847 0.030  | 8 (17)           | 6 (13)           | 0.563 0.118  |
| Viral hepatitis               | 44 (60)            | 26 (29)          | <0.001 0.673 | 20 (44)          | 22 (49)          | 0.673 0.089  |
| Liver cirrhosis               | 61 (84)            | 77 (85)          | 0.854 0.029  | 39 (81)          | 40 (83)          | 0.789 0.055  |
| Child–Pugh class (A/B)        | 55/18              | 69/22            | 0.943 0.011  | 38/10            | 33/15            | 0.245 0.239  |
| Child–Pugh score 5/6/7/8/9    | 38/17/8/5/5        | 52/17/11/8/3     | 0.756 0.215  | 28/10/6/2/2      | 26/7/6/6/3       | 0.591 0.347  |
| Other antidiabetic medications and statins |                  |                  |             |                  |                  |             |
| Sulfonylurea                  | 19 (26)            | 32 (35)          | 0.209 0.199  | 15 (31)          | 15 (31)          | 1.000 0.000  |
| Alpha glucosidase             | 15 (21)            | 13 (14)          | 0.290 0.166  | 8 (17)           | 8 (17)           | 1.000 0.000  |
| Thiazolidinedione             | 6 (8)              | 8 (9)            | 0.896 0.021  | 3 (6)            | 4 (9)            | 0.694 0.081  |
| DPP-4 inhibitor               | 5 (7)              | 25 (27)          | 0.001 0.569  | 27 (57)          | 27 (57)          | 1.000 0.000  |
| SGLT2i                        | 0 (0)              | 6 (7)            | 0.025 0.272  | 0 (0)            | 0 (0)            | 1.000 0.000  |
| Insulin                       | 64 (88)            | 76/83            | 0.454 0.119  | 41 (87)          | 41 (87)          | 1.000 0.000  |
| Statins                       | 12 (16)            | 24 (26)          | 0.127 0.244  | 19 (40)          | 19 (40)          | 1.000 0.000  |
| Laboratory data               |                    |                  |             |                  |                  |             |
| HbA1C, %                      | 6.8 (1.7)          | 7.0 (2.1)        | 0.557 0.041  | 6.6 (1.4)        | 6.9 (2.0)        | 0.852 0.060  |
| Creatinine (mg/dL)            | 0.96 (0.37)        | 0.91 (0.37)      | 0.351 0.276  | 1.00 (0.10)      | 0.93 (0.10)      | 0.329 0.330  |
| eGFR                          | 73 (33)            | 79 (33)          | 0.176 0.201  | 72 (40)          | 76 (29)          | 0.351 0.139  |
| Platelet, ×10^9/ul            | 119 (94)           | 135 (100)        | 0.010 0.239  | 130 (108)        | 135 (118)        | 0.516 0.108  |
| Prothrombin time, INR         | 1.13 (0.18)        | 1.08 (0.15)      | 0.018 0.328/  | 1.11 (0.16)      | 1.12 (0.21)      | 0.553 0.078  |
| Albumin, g/dL                 | 3.6 (0.7)          | 3.9 (0.7)        | 0.193 0.194  | 3.7 (0.7)        | 3.6 (0.9)        | 0.315 0.184  |
| Total bilirubin, mg/dL        | 0.9 (0.7)          | 0.7 (0.5)        | 0.009 0.284  | 0.8 (0.5)        | 0.8 (0.7)        | 0.770 0.054  |
| ALBI grade**                  | 27/43/3            | 54/34/3          | 0.006 0.461  | 22/23/2          | 22/22/3          | 0.985 0.097  |
| AFP, ng/ml                    | 7.3 (30.1)         | 5.0 (23.7)       | 0.241 0.178  | 5.9 (22.3)       | 7.5 (84.5)       | 0.513 0.332  |
| Tumor size, cm                | 2.7 (3.0)          | 3.3 (3.6)        | 0.026 0.228  | 3.2 (3.3)        | 3.3 (4.3)        | 0.307 0.201  |
| BCLC (0/A)                    | 25/48              | 17/74            | 0.023 0.358  | 14/33            | 10/37            | 0.344 0.196  |
| DEB-TACE                       | 5 (7)              | 12 (13)          | 0.186 0.212  | 5 (11)           | 6 (13)           | 0.748 0.066  |
| Follow-up duration (months)** | 22 (44)            | 13 (28)          | 0.190 0.293  | 46 (52)          | 25 (50)          | 0.148 0.395  |
Vol:.(1234567890)

www.nature.com/scientificreports/

Scientific Reports

and surgery3,6–8,10,12,34 A large-scale survey revealed that 28% of all TACE procedures were performed in early

less certain whether metformin has an adjuvant effect in cancer therapy37. Anecdotal studies have reported

therapeutics against HCC cells45. Preclinical studies have suggested that metformin inhibits tumor angiogenesis

liferation and metabolism41,42. However, metformin may also antagonize cisplatin-induced cytotoxicity in cer -
liver function, stage of HCC, comorbidities and use of other antidiabetic drugs by PS matching.

HCC. The beneficial effect of metformin remained significant after controlling potential confounders such as
to metformin was associated with favorable outcome when TACE was chosen as an initial therapy for single

been reported whether metformin affects the outcomes of TACE for HCC. In this study, we found that exposure

rate was not significantly different between the two groups (p = 0.260) (Fig. 2B). Progression-free survival was not
different between control and metformin group (p = 0.926) (Fig. 2C), either. Multivariate Cox regression
analysis showed that metformin administration was an independent predictor for LTR (hazard ratio [HR] 0.28,
95% CI 0.14–0.58, p = 0.001), along with hypertension, pre-treatment AFP levels and tumor size (Table 3). After
covariates were balanced by PS matching, metformin administration was still a significant predictor of low LTR
in patients with T2DM (HR 0.27, 95% confidence interval 0.11–0.70; p = 0.007, Supplementary Table 3). In met -
formin group, the daily dose of metformin did not have significant effect on local recurrence (OR 0.78 and 0.93,
p = 0.500 and 0.873 in all and PS-matched patients, respectively).

Discussion

Although TACE is not recommended as a first-line treatment for early HCC, it has been performed in early HCC
in real-world practice for variable reasons such as a bridge to transplantation33 or infeasible for local ablation
and surgery5,8–12,24 A large-scale survey revealed that 28% of all TACE procedures were performed in early
HCC, i.e., Barcelona Clinic Liver Cancer (BCLC) stage A4. Another global study reported that similar propor -
tion of patients with BCLC 0/A received TACE as an initial treatment34. Since the long-term local control rate is
relatively low in this setting6,8–12, it is a clinically relevant issue to enhance the response rate of TACE in BCLC
0/A. Our results also showed that only two-thirds of patients with single HCC obtained CR after TACE, and
one-thirds of the patients with CR eventually experienced local tumor recurrence.

Numerous epidemiologic studies reported association between metformin use and decreased risk of certain
Cancers such as pancreatic cancer and colorectal cancer in patients with T2DM35. In terms of HCC, meta-analyses
and large-scale cohort studies have shown that metformin administration is associated with a reduced risk of
HCC16–18. Controversy still exists, however, on the association between cancer risks and metformin36. It is even
less certain whether metformin has an adjuvant effect in cancer therapy37. Anecdotal studies have reported
favorable effects of metformin after resection, radiotherapy, and ablation for HCC38–40. However, it has not yet
been reported whether metformin affects the outcomes of TACE for HCC. In this study, we found that exposure
to metformin was associated with favorable outcome when TACE was chosen as an initial therapy for single
HCC. The beneficial effect of metformin remained significant after controlling potential confounders such as
liver function, stage of HCC, comorbidities and use of other antidiabetic drugs by PS matching.

Metformin activates 5'-AMP-activated protein kinase (AMPK), which in turn may suppress tumor cell pro-
liferation and metabolism41,42. However, metformin may also antagonize cisplatin-induced cytotoxicity in cer -
tain cancer cells42. The biological mechanisms underlying our observations are not certain at the present time.
TACE induces HCC cell death by increasing the local concentration of cytotoxic drugs and causing ischemia43.
However, TACE-induced ischemia may also lead to neo-angiogenesis of residual HCC via increased local HIF-1a and
vascular endothelial growth factor concentrations43. Furthermore, hypoxia may confer resistance to chemothera-
peutics against HCC cells45. Preclinical studies have suggested that metformin inhibits tumor angiogenesis

![Table 1. Comparison of baseline characteristics between diabetic patients with or without metformin therapy before TACE for single nodular HCC. AFP alpha-fetoprotein, ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, CKD chronic kidney disease, DEB drug-eluting bead, DPP-4 dipeptidyl peptidase-4, HbA1C hemoglobin A1c (glycated), INR international normalized ratio, PS propensity score, RFA radiofrequency ablation, SMD standardized mean difference. Categorical variables are presented as numbers (%), and tested using chi-square test. Continuous variables are presented as median (interquartile range), and p-values were calculated using Mann–Whitney U test. *Heavy alcohol consumption was defined as chronic consumption of > 40 g of alcohol per day. **Coronary heart disease, congestive heart failure and chronic obstructive pulmonary disease. ***For patients with complete response after TACE.](https://doi.org/10.1038/s41598-022-18341-2)

| Table 1. Comparison of baseline characteristics between diabetic patients with or without metformin therapy before TACE for single nodular HCC. AFP alpha-fetoprotein, ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, CKD chronic kidney disease, DEB drug-eluting bead, DPP-4 dipeptidyl peptidase-4, HbA1C hemoglobin A1c (glycated), INR international normalized ratio, PS propensity score, RFA radiofrequency ablation, SMD standardized mean difference. Categorical variables are presented as numbers (%), and tested using chi-square test. Continuous variables are presented as median (interquartile range), and p-values were calculated using Mann–Whitney U test. *Heavy alcohol consumption was defined as chronic consumption of > 40 g of alcohol per day. **Coronary heart disease, congestive heart failure and chronic obstructive pulmonary disease. ***For patients with complete response after TACE. |
|--------------|--------|--------|--------|--------|--------|
| All patients | Control n = 73 | Metformin n = 91 | Odds ratio | 95% CI | P value |
| Objective response rate (%) | 44 (60.3) | 72 (79.1) | 2.50 | 1.25–4.98 | 0.009 |
| Complete response (%) | 39 (53.4) | 51 (56.0) | 1.11 | 0.60–2.06 | 0.738 |
| Partial response (%) | 5 (6.9) | 21 (23.1) | | | |
| Stable disease (%) | 23 (31.5) | 15 (16.5) | | | |
| Progressive disease (%) | 6 (8.2) | 4 (4.4) | | | |
| PS-matched patients | Control n = 47 | Metformin n = 47 | Odds ratio | 95% CI | P value |
| Objective response rate (%) | 27 (57.5) | 37 (78.7) | 2.74 | 1.11–6.79 | 0.029 |
| Complete response (%) | 25 (53.2) | 25 (53.2) | 1.00 | 0.44–2.25 | 1.000 |
| Partial response (%) | 2 (4.2) | 12 (25.5) | | | |
| Stable disease (%) | 16 (34.0) | 7 (14.9) | | | |
| Progressive disease (%) | 4 (8.5) | 3 (6.4) | | | |

![Table 2. Initial radiological response to TACE according to metformin administration. Objective response rate: complete response + partial response.](https://doi.org/10.1038/s41598-022-18341-2)

| Table 2. Initial radiological response to TACE according to metformin administration. Objective response rate: complete response + partial response. |
|-----------------|--------|--------|--------|
| Objective response rate (%) | 27 (57.5) | 37 (78.7) | 2.74 |
| Complete response (%) | 25 (53.2) | 25 (53.2) | 1.00 |
| Partial response (%) | 2 (4.2) | 12 (25.5) | |
| Stable disease (%) | 16 (34.0) | 7 (14.9) | |
| Progressive disease (%) | 4 (8.5) | 3 (6.4) | |

![Scientific Reports](https://doi.org/10.1038/s41598-022-18341-2)
by inhibiting the HIF-1a and VEGF-signaling pathways. Metformin may also attenuate hypoxia-induced resistance to chemotherapeutics in the hepatoma cells. Thus, we speculate that metformin creates favorable environment for TACE-induced cell death in the liver, leading to enhanced tumor response to TACE and subsequently less frequent local relapse. This hypothesis may explain the finding that metformin use was associated with a lower risk of local recurrence but overall recurrence and PFS were not affected, possibly due to the high incidence of metachronous multiple HCC in our patients. Consecutive ablation therapy may also have achieved further local HCC control in patients without CR after initial TACE, reducing the potential beneficial effect
of metformin in terms of PFS. We do not believe that metformin per se has sufficient antitumor effect to suppresses intrahepatic metastasis or multicentric HCC, because HCC developed while many of our patients were on metformin. However, the exact mechanism of action of metformin on TACE response needs to be explored in further studies.

Our multivariate model showed that tumor size was an additional independent predictor for initial TACE response and local recurrence. Size of HCC has repeatedly been reported to predict aggressive tumor behavior and local control failure after TACE. Although TACE may have favorable outcome comparable to local ablation therapy as an initial treatment for single nodular HCC, and a recent guideline recommends TACE for early HCC in selected cases, our data reconfirm that TACE may not be sufficient for local control of early HCC with large tumor size. We believe our study may provide useful background for developing a new strategy on locoregional therapy for early HCC.

Our patients received metformin for variable duration and with different doses. Multivariate analyses showed significant association between daily dose of metformin and TACE responses only in PS-matched patients, and it is clear whether metformin doses may have significant impact. It is also not certain whether maintenance of metformin other than peri-TACE dosage may affect the local recurrence. Optimal scheduling of metformin may need to be explored by controlled trials.

The present study had other limitations. Since this was a retrospective single-center study with limited number of patients in each group enrolled over a wide time interval, further validation is warranted in larger number of patients prospectively. Second, we do not have data regarding the reason(s) why control patients did not receive metformin, currently first line therapy, because choice of antidiabetic drugs may potentially introduce selection bias. It is our speculation that some patients may have switched over to insulin, and other many have started and modified oral antidiabetic drugs other than metformin long before metformin has become the first-line therapy. To minimize selection bias, we balanced the use of other antidiabetic drugs by PS matching. Third, the initial response and LTR were investigated as surrogate markers of the metformin effect on the TACE anti-tumor

Table 3. Cox regression analysis for predictors of local HCC recurrence in all diabetic patients with complete response after TACE (N = 90). TACE transarterial chemoembolization, HCC hepatocellular carcinoma, HR hazard ratio, CI confidence interval, AFP alpha-fetoprotein, INR international normalized ratio, RFA radiofrequency ablation.
efficacy rather than overall survival. However, survival may be more dependent on subsequent therapies against local and/or distant HCC recurrence. Lastly, our analysis was limited to early HCC, and it is unknown whether metformin would augment the efficacy of TACE in more advanced disease, i.e., BCLC-B for whom TACE is recommended as a first-line therapy. This clinically important issue may be addressed by further prospective trials.

In summary, metformin administration was independently associated with an increased initial response after TACE for single HCC in patients with T2DM. Moreover, patients who achieved CR after TACE showed lower local recurrence when exposed to metformin.

Methods

Study population and data collection. This retrospective cohort analysis included patients with Barcelona Clinic Liver Cancer (BCLC) stage 0/A single nodular HCC who underwent TACE as an initial treatment between April 2003 and February 2020 in a tertiary referral hospital in South Korea. Demographic, clinical, and laboratory data were retrieved using our hospital’s clinical data warehouse package of the electronic medical record system. The study protocol was approved by Seoul National University Bundang Hospital Institutional Review Board (IRB No. B-2006/618-107), in accordance with the Declaration of Helsinki Ethical Principles for Medical Research involving human subjects. Seoul National University Bundang Hospital Institutional Review Board also waived informed consent due to the retrospective nature of this study and minimal expected risk to subjects.

History of all prescribed medications were retrieved by using electronic medical record system of our institution. Use of metformin and other medications listed in Table 1 was defined as presence of corresponding prescription(s) during the in-hospital admission period for the TACE procedure, which typically took 3–5 days.

Patients who stopped metformin before TACE were classified as control, and patients who initiated metformin therapy after TACE were excluded from analysis.

Diagnosis of HCC was confirmed based on histopathology or radiologic criteria. Patients were excluded from the study if they had (1) incomplete imaging study, (2) vascular or ductal invasion or distant metastasis, and (3) Child–Pugh class C cirrhosis. Liver cirrhosis was diagnosed histologically or clinically as previously reported: ultrasound features of cirrhosis (coarse liver echotexture with nodularity) plus evidence of portal hypertension including ascites, splenomegaly, thrombocytopenia (< 100 × 109/L) and varices. T2DM was diagnosed following the American Diabetes Association guidelines. Information about alcohol consumption was retrieved from the medical records. Attending hepatologists (GH Choi, ES Jang, SH Jeong and JW Kim) assessed the history of alcohol use by using structured fields of status, types of alcohol, amount of alcohol/week. Heavy alcohol consumption was defined as chronic consumption of > 40 g of alcohol per day.

Treatment selection. The recommendation for treatment selection of single nodular HCC was made by a multidisciplinary tumor board which was comprised of hepatologists, surgeons, and interventional radiologists, in accordance with the general principles of current guidelines. TACE had been performed for early (BCLC 0/A) HCC in this study for various reasons: initial misclassification (BCLC B), patients’ preference for non-invasive procedure, or tumor location not feasible for complete ablation. Combined RFA and TACE was performed if RFA was planned for single nodular HCC but the tumor nodule could not be localized by ultrasound: lipiodol-drug embolism was visualized for targeting either by ultrasound or cone beam CT.

TACE procedures. A 5-F angiographic catheter was introduced (RH; Cook, Bloomington, Indiana) to the right femoral artery and visceral arteriograms were obtained to select the tumor-feeding vessels. A 3-F (Renegade, Boston Scientific, Natick, MA) or 2-F (Progreat, Terumo, Tokyo, Japan) microcatheter was used to super-select the tumor-feeding arteries. After placement of the microcatheter tip in the proper feeders, emulsion of 10–50 mg of doxorubicin hydrochloride (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Korea) solution in non-ionic contrast media mixed with 2–10 mL of iodized oil (Lipiodol Ultra Fluid; Andre Guerbet, Aulnay-sous-Bois, France) in a 1:4 volume ratio was administered, and the tumor-feeding arteries were subsequently embolized with gelatin sponge particles (Gelfoam; Upjohn, Kalamazoo, MI). Cone beam CT was routinely used to assess the effectiveness of embolization. For drug-eluting bead (DEB)-TACE, 50–75 mg of doxorubicin was loaded into one vial containing 2 mL of microspheres (DC Bead, BTG) for 2 h and the preparation was suspended in 50 mL of a mixture of normal saline and contrast agent at a 1:1 ratio. One or two vials of DEB agent of 100–300 or 300–500 μm were used. DEB particles were slowly infused through tumor-feeding arteries until near stasis of arterial flow. The choice of conventional vs. DEB-TACE was on the discretion of attending physicians, taking patients’ preference into consideration.

Assessment of treatment response. Liver four-phase dynamic computed tomography (CT) or magnetic resonance (MR) images were obtained at baseline, and CT was followed 1 month after TACE for the assessment of TACE response. Thereafter, CT or MR imaging was obtained at 3–6 months of interval. The target lesion’s treatment response was assessed according to the modified Response Evaluation Criteria in Solid Tumors; complete response (CR) was defined as the disappearance of any intratumoral arterial enhancement in the target lesion. Partial response (PR) was defined as > 30% decrease in the sum of the longest viable tumor diameters of the target lesion. The objective response rate (ORR) was defined as the combined CR and PR rate of the target lesion only, excluding new lesions’ assessment. The radiologic response was assessed either by four radiologists of more than 15 years of experience in our institution, or by one of the authors (WJJ) who were not aware of the history of metformin exposure at the time of imaging analysis.

Local tumor recurrence (LTR) in patients with CR after TACE was defined as the appearance of new tumor foci at the embolized and/or ablative tumor margins. Overall recurrence was defined as presence of either LTR...
and/or intrahepatic distant recurrence. LTR-free survival was defined as the interval between the initial TACE and the first evidence of LTR. Overall recurrence-free survival was defined as the interval between initial TACE and the first evidence of overall recurrence. Progression-free survival (PFS) was defined as the interval between TACE and the first evidence of HCC progression (local tumor progression, intrahepatic distant recurrence, gross vascular invasion, or extrahepatic distant metastasis)\(^1\). Overall survival was not assessed due to lack of complete survival data.

**Statistical analysis.** Continuous variables were tested using the Student’s t-test or Mann–Whitney test, and categorical variables were tested using the Chi-square test. Kaplan–Meier plots and log-rank tests were used to assess LTR, overall recurrence and PFS. Logistic regression analysis was used to determine the predictors of the objective response after TACE. In patients with CR after TACE, Cox regression analysis was used to assess the independent predictors of LTR and overall recurrence. All variables with univariate regression p value < 0.1 were included in multivariate regression analysis. Subgroup analyses were conducted on patients with T2DM or CR after TACE. Propensity score (PS) matching was performed to balance the following variables between diabetic patients with and without metformin: age, chronic viral hepatitis, liver cirrhosis, use of anti-diabetic drugs (sulfonylurea, DPP-4 inhibitors, SGLT2 inhibitors and insulins) and statins, platelet counts, prothrombin time, ALBI-score, pre-treatment HCC size. PS was calculated with complete case analysis and logistic regression model by using MatchIt R package (version 4.1.0). One-to-one matching was performed with nearest neighbor matching algorithm and caliper of 0.2 of the standard deviation of the estimated propensity scores. Balancing diagnostics were assessed by both p value and standardized mean difference (SMD). Statistical analysis was performed using STATA ver. 14.2 or R package ver. 4.0.2.

Received: 15 December 2021; Accepted: 9 August 2022
Published online: 25 August 2022

**References**

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 68, 394–424. https://doi.org/10.3322/cajc.21492 (2018).
2. Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J. Hepatol.* 76, 681–693. https://doi.org/10.1016/j.jhep.2021.11.018 (2022).
3. Yang, H. J. et al. Small single-nodule hepatocellular carcinoma: Comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. *Radiology* 271, 909–918. https://doi.org/10.1148/radiol.131131760 (2014).
4. Bargellini, L. et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study. *Eur. J. Radiol.* 81, 1173–1178. https://doi.org/10.1016/j.ejrad.2011.03.046 (2012).
5. Hyun, D. et al. Early stage hepatocellular carcinomas not feasible for ultrasound-guided radiofrequency ablation: Comparison of transarterial chemoembolization alone and combined therapy with transarterial chemoembolization and radiofrequency ablation. *Cardiovasc. Intervent. Radiol.* 39, 417–425. https://doi.org/10.1007/s00270-015-1194-0 (2016).
6. Yun, B. Y. et al. Prognosis of early-stage hepatocellular carcinoma: Comparison between trans-arterial chemoembolization and radiofrequency ablation. *Cancers* https://doi.org/10.3390/cancers12092527 (2020).
7. Baek, M. Y. et al. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. *Korean J. Intern. Med.* 34, 1223–1232. https://doi.org/10.3904/kjim.2018.058 (2019).
8. Hsu, K. F. et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. *Eur. J. Radiol.* 81, 466–471. https://doi.org/10.1016/j.ejrad.2010.12.058 (2012).
9. Kim, J. H. et al. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. *Clin. Mol. Hepatol.* 23, 42–50. https://doi.org/10.3350/cmh.2016.0058 (2017).
10. Song, Y. G. et al. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: A retrospective cohort study of 116 patients. *Acta Radiol.* 56, 70–77. https://doi.org/10.1177/0284185114520857 (2015).
11. Kim, W. et al. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: Comparison with TACE or RFA monotherapy. *Abdom. Radiol.* 44, 2283–2292. https://doi.org/10.1007/s00261-019-01952-1 (2019).
12. Terzi, E. et al. TACE performed in patients with a single nodule of hepatocellular carcinoma. *BMC Cancer* 14, 601. https://doi.org/10.1186/1471-2407-14-601 (2014).
13. Peng, Z. W. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial. *J. Clin. Oncol.* 31, 426–432. https://doi.org/10.1200/JCO.2012.42.9936 (2013).
14. Ren, Y. et al. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: Results of a single-center retrospective case control study. *BMJ Cancer* 19, 983. https://doi.org/10.1186/s12885-019-6237-5 (2019).
15. Zhang, Y. J., Chen, M. S., Chen, Y., Lai, W. Y. & Peng, Z. Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma. *JAMA Netw. Open* 4, e212692. https://doi.org/10.1001/jamanetworkopen.2021.212692 (2021).
16. Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. *Am. J. Gastroenterol.* 108, 881–891. https://doi.org/10.1038/ajg.2013.5 (2013) (Quiz 892).
17. Ma, S., Zheng, Y., Xiao, Y., Zhou, P. & Tan, H. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. *Medicine* 96, e6888. https://doi.org/10.1097/MD.0000000000006888 (2017).
18. Iseng, C. H. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. *Liver Int.* 38, 2018–2027. https://doi.org/10.1111/liv.13873 (2018).
19. Petrushev, B. et al. Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. *Exp. Oncol.* 34, 17–24 (2012).
20. Guo, Z. et al. Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. *Cancer Sci.* 107, 507–513. https://doi.org/10.1111/cas.12885 (2016).
59. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur. J. Cancer* **45**, 228–247. [https://doi.org/10.1016/j.ejca.2008.10.026](https://doi.org/10.1016/j.ejca.2008.10.026) (2009).

60. Ahmed, M. et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria: A 10-year update. *Radiology* **273**, 241–260. [https://doi.org/10.1148/radiol.14132958](https://doi.org/10.1148/radiol.14132958) (2014).

61. Park, C. et al. Imaging predictors of survival in patients with single small hepatocellular carcinoma treated with transarterial chemoembolization. *Korean J. Radiol.* **22**, 213–224. [https://doi.org/10.3348/kjr.2020.0329](https://doi.org/10.3348/kjr.2020.0329) (2021).

**Author contributions**

Guarantor of the article: J.W.K. Specific author contributions: W.J.J. and J.W.K. planned the study, W.J.J., S.J., W.J.C., J.P., G.H.C., E.S.J., S.H.J., W.S.C., J.H.L., C.J.Y. and J.W.K. conducted the study; W.J.J. and J.W.K. collected data; W.J.J., S.J., W.J.C., J.P., G.H.C., E.S.J., S.H.J. and J.W.K. interpreted data; W.J.J., S.J., W.J.C., J.P., G.H.C., E.S.J., S.H.J., W.S.C., J.H.L., C.J.Y. and J.W.K. drafted the manuscript.

**Funding**

This work was partly supported by a grant to J-W Kim, funded by Seoul National University Bundang Hospital/ SK Telecom (06-2013-104).

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1038/s41598-022-18341-2](https://doi.org/10.1038/s41598-022-18341-2).

**Correspondence** and requests for materials should be addressed to J.-W.K.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access] This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2022